Conversion to Rapamycin Immunosuppression for Malignancy After Kidney Transplantation: Case Reports
Authors:
- E. AbruzzeseE. Abruzzese
- G. TisoneGTG. Tisone
- 1 July 2007
- journal article
- case report
- Published by Elsevier in Transplantation Proceedings
- Vol. 39 (6) , 2036-2037
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Sirolimus-Induced Remission of Posttransplantation Lymphoproliferative DisorderAmerican Journal of Kidney Diseases, 2006
- Individualization of Immunosuppressive Therapy. III. Sirolimus Associated With a Reduced Incidence of MalignancyTransplantation Proceedings, 2006
- Sirolimus Therapy after Early Cyclosporine Withdrawal Reduces the Risk for Cancer in Adult Renal TransplantationJournal of the American Society of Nephrology, 2006
- Sirolimus for Kaposi's Sarcoma in Renal-Transplant RecipientsNew England Journal of Medicine, 2005
- Cancer after Kidney Transplantation in the United StatesAmerican Journal of Transplantation, 2004
- Rapamycin treatment at immunosuppressive doses affects tumor blood vessel circulationTransplantation Proceedings, 2003
- Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatmentTransplant International, 2003